RobbScottFriedmanMD
Oncology • South Weymouth, MAHematologic Oncology
Clinical Instructor in Medicine, Harvard Medical School
Dr. Friedman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dana Farber Cancer Institute
South Shore Hospital
South Weymouth, MA 02190Phone+1 781-624-4800
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2002 - 2004
Georgetown University School of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 1999 - Present
MA State Medical License 2004 - 2026
VA State Medical License 2002 - 2004
MD State Medical License 1998 - 2000
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Publications & Presentations
PubMed
- Longitudinal Patient-Reported Outcomes in Older Adults With Aggressive Lymphomas Receiving Chemoimmunotherapy.P Connor Johnson, Jeremy S Abramson, Ann S LaCasce, Philippe Armand, Jeffrey Barnes
Journal of the National Comprehensive Cancer Network. 2025-02-19 - Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.Andrew J Yee, Jacob P Laubach, Erica L Campagnaro, Brea C Lipe, Omar Nadeem
Blood Advances. 2024-12-03 - Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.Ronald Nemec, Marielle Scherrer-Crosbie, Jeremy S Abramson, Robert Redd, Hannah K Gilman
Leukemia & Lymphoma. 2024-06-01
Abstracts/Posters
- Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for ImmunotherapyRobb S Friedman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple MyelomaRobb S Friedman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaRobb S Friedman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
